Related Experiment Video

Updated: May 22, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Targeted therapy for triple-negative breast cancer: where are we?

Michael J Duffy1, Patricia M McGowan, John Crown

  • 1UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland. michael.j.duffy@ucd.ie

International Journal of Cancer
|May 15, 2012
PubMed

Insights

Triple-negative breast cancer lacks targeted therapies. Research identifies potential targets like EGFR and PARP1/2, suggesting combination treatments for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative (TN) breast cancer lacks targeted therapies, unlike other subtypes.
  • Estrogen receptor (ER), progesterone receptor (PR), and HER2 negativity defines TN breast cancer.
  • Tumor heterogeneity presents a challenge for single-agent therapies in TNBC.

Purpose of the Study:

  • To review potential molecular targets for TN breast cancer treatment.
  • To explore rational therapeutic strategies for TNBC based on preclinical findings.

Main Methods:

  • Literature review of preclinical studies on TN breast cancer.
  • Identification of potential therapeutic targets including EGFR, SRC, MET, and PARP1/2.
  • Analysis of therapeutic strategies including combination therapies.

Main Results:

  • Several molecular targets (EGFR, SRC, MET, PARP1/2) show promise in preclinical models.
  • No single targeted therapy is likely to be effective for all TNBC patients due to heterogeneity.
  • Biomarker-driven approaches and combination therapies are promising.

Conclusions:

  • Targeted therapies for TN breast cancer require further investigation.
  • Combination strategies, potentially with chemotherapy, offer a rational path forward.
  • Biomarker-driven approaches are crucial for personalized TNBC treatment.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...